COMPANY PROFILE

NTX

Creating revolutionary textile solutions through continuous research and innovation that are ecologically and economically sustainable

ChinaFounded 2000Fashion

Valuation $1–2.5B Last recorded · 2022

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About NTX

NewTech Textile operates in the textile industry, focusing on innovative and sustainable solutions. The company serves a diverse range of clients including fashion brands, healthcare providers, and industrial manufacturers. Its core offerings include next-generation textile coloration technology and advanced respirators like the Super N95, designed to combat COVID-19. NewTech Textile's business model revolves around commercializing its proprietary technologies, which are aimed at enhancing performance and sustainability in textile production. Revenue is generated through the sale of these advanced textile products and licensing of their technologies to other manufacturers. The company operates on a global scale, collaborating with partners to revolutionize traditional textile processes and promote eco-friendly practices.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2000
Headquarters: China
Employees: 16
Open positions: None listed
Dealroom signal: 27.7/100
Industry: Fashion
Sector: Fashion, Rumoured $1B
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Aug 2022	$200M	$800M	NRL Capital · Index Capital · Centurium Capital	↗
SERIES COther financing	Sep 2021	$0	—	Undisclosed	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

NTX website traffic

Latest recorded traffic for NTX is 1.7K monthly website visits, up 30.8% over the last three months. NTX's team declined 20% over the past year.

Latest monthly visits1.7K 3-month web change+30.8% 1-year team growth-20%

Monthly website visitsOct 2022–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTcAMPfield TherapeuticsOral biopharmaceutical therapies for inflammatory bowel disease and other immune-mediated inflammatory diseases	San Diego, United States	Operational	19	$180M	$720M
BMBeeline MedicinesPrecision therapies for autoimmune and inflammatory diseases.	Stamford, United States	Operational
ATAirNexis TherapeuticsPulmonary disease therapeutics for chronic obstructive pulmonary disease	Palo Alto, United States	Operational
ATAlveus TherapeuticsNext-generation obesity and metabolic disease therapies	Philadelphia, United States	Operational
BBBraveheart BioLate-stage therapeutics for hypertrophic cardiomyopathy	San Francisco, United States	Operational
EXExcellergyTrifunctional inhibitors for severe allergic disease control	Palo Alto, United States	Acquired
CTCrystalys TherapeuticsClinical-stage biopharmaceutical developing therapies for gout	San Diego, United States	Operational
ATAntares TherapeuticsDevelopment of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments	Boston, United States	Operational